Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Targeting IDH1 as a Prosenescent Therapy in High-grade Serous Ovarian Cancer.

Dahl ES, Buj R, Leon KE, Newell JM, Imamura Y, Bitler BG, Snyder NW, Aird KM.

Mol Cancer Res. 2019 May 20. doi: 10.1158/1541-7786.MCR-18-1233. [Epub ahead of print]

PMID:
31110157
2.

NAD+ metabolism governs the proinflammatory senescence-associated secretome.

Nacarelli T, Lau L, Fukumoto T, Zundell J, Fatkhutdinov N, Wu S, Aird KM, Iwasaki O, Kossenkov AV, Schultz D, Noma KI, Baur JA, Schug Z, Tang HY, Speicher DW, David G, Zhang R.

Nat Cell Biol. 2019 Mar;21(3):397-407. doi: 10.1038/s41556-019-0287-4. Epub 2019 Feb 18.

PMID:
30778219
3.

Jumonji C Demethylases in Cellular Senescence.

Leon KE, Aird KM.

Genes (Basel). 2019 Jan 9;10(1). pii: E33. doi: 10.3390/genes10010033. Review.

4.

Simultaneous isotope dilution quantification and metabolic tracing of deoxyribonucleotides by liquid chromatography high resolution mass spectrometry.

Kuskovsky R, Buj R, Xu P, Hofbauer S, Doan MT, Jiang H, Bostwick A, Mesaros C, Aird KM, Snyder NW.

Anal Biochem. 2019 Mar 1;568:65-72. doi: 10.1016/j.ab.2018.12.023. Epub 2018 Dec 31.

PMID:
30605633
5.

GPx3 supports ovarian cancer progression by manipulating the extracellular redox environment.

Worley BL, Kim YS, Mardini J, Zaman R, Leon KE, Vallur PG, Nduwumwami A, Warrick JI, Timmins PF, Kesterson JP, Phaëton R, Lee NY, Walter V, Endres L, Mythreye K, Aird KM, Hempel N.

Redox Biol. 2018 Nov 17. pii: S2213-2317(18)30891-7. doi: 10.1016/j.redox.2018.11.009. [Epub ahead of print]

6.

CLIC1 and CLIC4 complement CA125 as a diagnostic biomarker panel for all subtypes of epithelial ovarian cancer.

Singha B, Harper SL, Goldman AR, Bitler BG, Aird KM, Borowsky ME, Cadungog MG, Liu Q, Zhang R, Jean S, Drapkin R, Speicher DW.

Sci Rep. 2018 Oct 3;8(1):14725. doi: 10.1038/s41598-018-32885-2.

7.

Deoxyribonucleotide Triphosphate Metabolism in Cancer and Metabolic Disease.

Buj R, Aird KM.

Front Endocrinol (Lausanne). 2018 Apr 18;9:177. doi: 10.3389/fendo.2018.00177. eCollection 2018. Review.

8.

Ataxia-Telangiectasia Mutated Modulation of Carbon Metabolism in Cancer.

Dahl ES, Aird KM.

Front Oncol. 2017 Nov 29;7:291. doi: 10.3389/fonc.2017.00291. eCollection 2017. Review.

9.

Ovarian cancer: how can resistance to chemotherapy be tackled?

Karakashev S, Aird KM.

Future Oncol. 2017 Dec;13(30):2737-2739. doi: 10.2217/fon-2017-0235. Epub 2017 Nov 28. No abstract available.

PMID:
29182383
10.

ARID1A-mutated ovarian cancers depend on HDAC6 activity.

Bitler BG, Wu S, Park PH, Hai Y, Aird KM, Wang Y, Zhai Y, Kossenkov AV, Vara-Ailor A, Rauscher FJ III, Zou W, Speicher DW, Huntsman DG, Conejo-Garcia JR, Cho KR, Christianson DW, Zhang R.

Nat Cell Biol. 2017 Aug;19(8):962-973. doi: 10.1038/ncb3582. Epub 2017 Jul 24.

11.

HMGB2 orchestrates the chromatin landscape of senescence-associated secretory phenotype gene loci.

Aird KM, Iwasaki O, Kossenkov AV, Tanizawa H, Fatkhutdinov N, Bitler BG, Le L, Alicea G, Yang TL, Johnson FB, Noma KI, Zhang R.

J Cell Biol. 2016 Nov 7;215(3):325-334. Epub 2016 Oct 31.

12.

Corrigendum: sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance.

Kaur A, Webster MR, Marchbank K, Behera R, Ndoye A, Kugel CH, Dang VM, Appleton J, O'Connell MP, Cheng P, Valiga AA, Morissette R, McDonnell NB, Ferrucci L, Kossenkov AV, Meeth K, Tang HY, Yin X, Wood WH, Lehrmann E, Becker KG, Flaherty KT, Frederick DT, Wargo JA, Cooper ZA, Tetzlaff MT, Hudgens C, Aird KM, Zhang R, Xu X, Liu Q, Bartlett E, Karakousis G, Eroglu Z, Lo RS, Chan M, Menzies AM, Long GV, Johnson DB, Sosman J, Schilling B, Schadendorf D, Speicher DW, Bosenberg M, Ribas A, Weeraratna AT.

Nature. 2016 Sep 8;537(7619):254. doi: 10.1038/nature18939. Epub 2016 Jul 6. No abstract available.

PMID:
27383789
13.

Epigenetic synthetic lethality in ovarian clear cell carcinoma: EZH2 and ARID1A mutations.

Bitler BG, Aird KM, Zhang R.

Mol Cell Oncol. 2015 Apr 14;3(1):e1032476. doi: 10.1080/23723556.2015.1032476. eCollection 2016 Jan.

14.

Targeting RRM2 and Mutant BRAF Is a Novel Combinatorial Strategy for Melanoma.

Fatkhutdinov N, Sproesser K, Krepler C, Liu Q, Brafford PA, Herlyn M, Aird KM, Zhang R.

Mol Cancer Res. 2016 Sep;14(9):767-75. doi: 10.1158/1541-7786.MCR-16-0099. Epub 2016 Jun 13.

15.

sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance.

Kaur A, Webster MR, Marchbank K, Behera R, Ndoye A, Kugel CH 3rd, Dang VM, Appleton J, O'Connell MP, Cheng P, Valiga AA, Morissette R, McDonnell NB, Ferrucci L, Kossenkov AV, Meeth K, Tang HY, Yin X, Wood WH 3rd, Lehrmann E, Becker KG, Flaherty KT, Frederick DT, Wargo JA, Cooper ZA, Tetzlaff MT, Hudgens C, Aird KM, Zhang R, Xu X, Liu Q, Bartlett E, Karakousis G, Eroglu Z, Lo RS, Chan M, Menzies AM, Long GV, Johnson DB, Sosman J, Schilling B, Schadendorf D, Speicher DW, Bosenberg M, Ribas A, Weeraratna AT.

Nature. 2016 Apr 14;532(7598):250-4. doi: 10.1038/nature17392. Epub 2016 Apr 4.

16.

SPOP E3 Ubiquitin Ligase Adaptor Promotes Cellular Senescence by Degrading the SENP7 deSUMOylase.

Zhu H, Ren S, Bitler BG, Aird KM, Tu Z, Skordalakes E, Zhu Y, Yan J, Sun Y, Zhang R.

Cell Rep. 2015 Nov 10;13(6):1183-1193. doi: 10.1016/j.celrep.2015.09.083. Epub 2015 Oct 29.

17.

EglN2 associates with the NRF1-PGC1α complex and controls mitochondrial function in breast cancer.

Zhang J, Wang C, Chen X, Takada M, Fan C, Zheng X, Wen H, Liu Y, Wang C, Pestell RG, Aird KM, Kaelin WG Jr, Liu XS, Zhang Q.

EMBO J. 2015 Dec 2;34(23):2953-70. doi: 10.15252/embj.201591437. Epub 2015 Oct 22.

18.

ATM in senescence.

Aird KM, Zhang R.

Oncotarget. 2015 Jun 20;6(17):14729-30. No abstract available.

19.

PI3K therapy reprograms mitochondrial trafficking to fuel tumor cell invasion.

Caino MC, Ghosh JC, Chae YC, Vaira V, Rivadeneira DB, Faversani A, Rampini P, Kossenkov AV, Aird KM, Zhang R, Webster MR, Weeraratna AT, Bosari S, Languino LR, Altieri DC.

Proc Natl Acad Sci U S A. 2015 Jul 14;112(28):8638-43. doi: 10.1073/pnas.1500722112. Epub 2015 Jun 29.

20.

ATM couples replication stress and metabolic reprogramming during cellular senescence.

Aird KM, Worth AJ, Snyder NW, Lee JV, Sivanand S, Liu Q, Blair IA, Wellen KE, Zhang R.

Cell Rep. 2015 May 12;11(6):893-901. doi: 10.1016/j.celrep.2015.04.014. Epub 2015 Apr 30.

21.

Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers.

Bitler BG, Aird KM, Garipov A, Li H, Amatangelo M, Kossenkov AV, Schultz DC, Liu Q, Shih IeM, Conejo-Garcia JR, Speicher DW, Zhang R.

Nat Med. 2015 Mar;21(3):231-8. doi: 10.1038/nm.3799. Epub 2015 Feb 16.

22.

Metabolic alterations accompanying oncogene-induced senescence.

Aird KM, Zhang R.

Mol Cell Oncol. 2014 Dec 23;1(3):e963481. doi: 10.4161/23723548.2014.963481. eCollection 2014 Jul-Sep. Review.

23.

Nucleotide metabolism, oncogene-induced senescence and cancer.

Aird KM, Zhang R.

Cancer Lett. 2015 Jan 28;356(2 Pt A):204-10. doi: 10.1016/j.canlet.2014.01.017. Epub 2014 Jan 29. Review.

24.

Identification of ribonucleotide reductase M2 as a potential target for pro-senescence therapy in epithelial ovarian cancer.

Aird KM, Li H, Xin F, Konstantinopoulos PA, Zhang R.

Cell Cycle. 2014;13(2):199-207. doi: 10.4161/cc.26953. Epub 2013 Oct 29.

25.

Chromatin remodeling, BRCA1, SAHF and cellular senescence.

Tu Z, Aird KM, Zhang R.

Cell Cycle. 2013 Jun 1;12(11):1653-4. doi: 10.4161/cc.24986. Epub 2013 May 10. No abstract available.

26.

Suppression of nucleotide metabolism underlies the establishment and maintenance of oncogene-induced senescence.

Aird KM, Zhang G, Li H, Tu Z, Bitler BG, Garipov A, Wu H, Wei Z, Wagner SN, Herlyn M, Zhang R.

Cell Rep. 2013 Apr 25;3(4):1252-65. doi: 10.1016/j.celrep.2013.03.004. Epub 2013 Apr 4.

27.

Detection of senescence-associated heterochromatin foci (SAHF).

Aird KM, Zhang R.

Methods Mol Biol. 2013;965:185-96. doi: 10.1007/978-1-62703-239-1_12.

28.

RAS, cellular senescence and transformation: the BRCA1 DNA repair pathway at the crossroads.

Tu Z, Aird KM, Zhang R.

Small GTPases. 2012 Jul-Sep;3(3):163-7. doi: 10.4161/sgtp.19884. Epub 2012 Jul 1.

29.

XIAP inhibition and generation of reactive oxygen species enhances TRAIL sensitivity in inflammatory breast cancer cells.

Allensworth JL, Aird KM, Aldrich AJ, Batinic-Haberle I, Devi GR.

Mol Cancer Ther. 2012 Jul;11(7):1518-27. doi: 10.1158/1535-7163.MCT-11-0787. Epub 2012 Apr 16.

30.

Oncogenic RAS regulates BRIP1 expression to induce dissociation of BRCA1 from chromatin, inhibit DNA repair, and promote senescence.

Tu Z, Aird KM, Bitler BG, Nicodemus JP, Beeharry N, Xia B, Yen TJ, Zhang R.

Dev Cell. 2011 Dec 13;21(6):1077-91. doi: 10.1016/j.devcel.2011.10.010. Epub 2011 Dec 1.

31.

Cytotoxic effects of Mn(III) N-alkylpyridylporphyrins in the presence of cellular reductant, ascorbate.

Ye X, Fels D, Tovmasyan A, Aird KM, Dedeugd C, Allensworth JL, Kos I, Park W, Spasojevic I, Devi GR, Dewhirst MW, Leong KW, Batinic-Haberle I.

Free Radic Res. 2011 Nov;45(11-12):1289-306. doi: 10.3109/10715762.2011.616199. Epub 2011 Sep 27.

32.

ErbB1/2 tyrosine kinase inhibitor mediates oxidative stress-induced apoptosis in inflammatory breast cancer cells.

Aird KM, Allensworth JL, Batinic-Haberle I, Lyerly HK, Dewhirst MW, Devi GR.

Breast Cancer Res Treat. 2012 Feb;132(1):109-19. doi: 10.1007/s10549-011-1568-1. Epub 2011 May 11.

33.

Targeting GLI1 expression in human inflammatory breast cancer cells enhances apoptosis and attenuates migration.

Thomas ZI, Gibson W, Sexton JZ, Aird KM, Ingram SM, Aldrich A, Lyerly HK, Devi GR, Williams KP.

Br J Cancer. 2011 May 10;104(10):1575-86. doi: 10.1038/bjc.2011.133. Epub 2011 Apr 19.

34.

X-linked inhibitor of apoptosis protein inhibits apoptosis in inflammatory breast cancer cells with acquired resistance to an ErbB1/2 tyrosine kinase inhibitor.

Aird KM, Ghanayem RB, Peplinski S, Lyerly HK, Devi GR.

Mol Cancer Ther. 2010 May;9(5):1432-42. doi: 10.1158/1535-7163.MCT-10-0160. Epub 2010 Apr 20.

35.

Cellular uptake of neutral phosphorodiamidate morpholino oligomers.

Iversen PL, Aird KM, Wu R, Morse MM, Devi GR.

Curr Pharm Biotechnol. 2009 Sep;10(6):579-88. Epub 2009 Sep 1.

PMID:
19619124
36.

Trastuzumab signaling in ErbB2-overexpressing inflammatory breast cancer correlates with X-linked inhibitor of apoptosis protein expression.

Aird KM, Ding X, Baras A, Wei J, Morse MA, Clay T, Lyerly HK, Devi GR.

Mol Cancer Ther. 2008 Jan;7(1):38-47. doi: 10.1158/1535-7163.MCT-07-0370.

Supplemental Content

Support Center